IL-6 promotes T cell activation and production in acute inflammatory conditions, initiates B cell differentiation, regulates liver production of acute phase reactants, and stimulates hypothalamus-pituitary-adrenal system, which is important in acute inflammation . Nevertheless prolonged IL-6 exposition activates apoptosis . According to recent studies increased levels of IL-6 increase cardiovascular disease risks . The aim of the study was to explore IL-6 basic levels in chronic congestive heart failure patients, as in risk group in COVID-19, and various factors (demographic or clinical) in various groups of IL-6 basic levels . We used consecutive sampling approach to recruit 96 congestive heart failure patients and 34 persons without the condition as controls . Hematologic, biochemical and immunologic parameters were measured using conventional methods . We used descriptive statistics for demographic parameters . We compared mean values of hematologic and biochemical parameters in cases and controls using independent sample t test and explored differences within the congestive heart failure group (further separated in 3 groups according to IL-6 levels) using one way ANOVA test, with further post-hoc analysis . Levels of IL-6 are statistically significantly higher in CHF patients; groups differ in co-morbidity, also abdominal obesity is more prevalent in diseased group . Difference between groups is significant in a number of pro-inflammation, coagulation, hematology parameters . It is also important to note that the CHF group showed a number of differences in sub-groups according to IL-6 levels, risks of CHF and comorbidity deterioration risks therefore are suggested to be different.